lenalidomide + placebo

Lenalidomide + placebo refers to the combination of active drug lenalidomide and an inert substance (placebo) used as a control in randomized, double-blind clinical trials. Lenalidomide is an immunomodulatory small molecule primarily indicated for hematologic malignancies such as multiple myeloma and myelodysplastic syndromes (MDS), especially those with deletion 5q cytogenetic abnormality. The mechanism of action includes modulation of the immune system, inhibition of angiogenesis, and direct anti-neoplastic effects through multiple cellular targets. In clinical studies comparing lenalidomide to placebo in patients with low-risk or transfusion-dependent MDS with del(5q), lenalidomide significantly delayed progression to transfusion dependency and improved rates of red blood cell transfusion independence, with a manageable safety profile[1][2][3][7]. Placebo serves as a negative control without pharmacological activity.